Form 4: Adaptimmune Therapeutics PLC: Chief Scientific Officer Acquires Options to Purchase Ordinary Shares
SEC Form 4
Joanna Elizabeth Brewer, Chief Scientific Officer of Adaptimmune Therapeutics PLC, reports the acquisition of options to purchase ordinary shares in the company.
Summary
- Joanna Elizabeth Brewer, the Chief Scientific Officer of Adaptimmune Therapeutics PLC, filed a Form 4 detailing changes in beneficial ownership.
- The report indicates the acquisition of options to purchase 1,612,032 ordinary shares at an exercise price of $0.1, exercisable starting February 20, 2026, with monthly installments thereafter.
- Additionally, Brewer acquired options to purchase 1,074,696 ordinary shares at an exercise price of $0.0013, exercisable starting February 20, 2026, with annual installments thereafter.
- Both sets of options expire on February 20, 2035.
- The reported transactions reflect direct ownership of the derivative securities.
Sentiment
Score: 6
Explanation: The document itself is neutral, simply reporting a transaction. The sentiment is slightly positive as it indicates executive alignment with company success through stock options.
Positives
- The acquisition of options by a key executive could be interpreted as a sign of confidence in the company's future prospects.
Industry Context
This filing is a routine disclosure related to executive compensation and is common in the biotechnology industry.
Comparison to Industry Standards
- Option grants are a standard form of compensation for executives in the biotechnology industry, often used to align management's interests with those of shareholders.
- The vesting schedules (monthly and annual installments) are typical for executive option grants.
- Comparing the size of the option grants to those of executives at similar-sized biotechnology companies would provide further context.
Stakeholder Impact
- The option grants could potentially dilute existing shareholders if the options are exercised in the future.
Key Dates
| Date | Description |
|---|---|
| 02/20/2025 | Date of Earliest Transaction |
| 02/20/2026 | First exercisable date for both option grants |
| 01/20/2028 | End of monthly installments for the first option grant |
| 02/20/2029 | End of annual installments for the second option grant and final installment for the first option grant |
| 02/20/2035 | Expiration date for both option grants |
Keywords
Adaptimmune Therapeutics, Joanna Brewer, Form 4, Beneficial Ownership, Options, Ordinary Shares, Chief Scientific Officer, ADAP
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.